Optithera partners in CONNECT, funded by the Terry Fox Research Institute’s Digital Health Innovation Fund
The Terry Fox Research Institute’s Digital Health & Discovery Platform (DHDP) has selected CONNECT among 14 pan-Canadian projects funded through its first Digital Health Innovation Fund. The project brings together Omnimed, Optithera and Université de Montréal. CONNECT will build a secure “diabetes prescriptome” linking Omnimed’s real-world EMR data, Optithera’s polygenic risk scores and validated treatment […]
Optithera and Omnimed receive funding for CIRCULATE, an AI project in cardio-rheumatology care
Optithera and Omnimed have been selected under Québec’s 2025-2026 call for innovation projects in artificial intelligence and quantum technologies, announced by Daniel Bernard, Minister Delegate for the Economy and Small and Medium-Sized Enterprises. The CIRCULATE project, valued at 3.1 million dollars, receives 1.1 million dollars in government support through MEDTEQ+. CIRCULATE (Intersectoral Collaboration to Improve […]
GENOCORDIA test now protected by a United States patent
The United States Patent and Trademark Office (USPTO) has granted a patent protecting the GENOCORDIA test (U.S. Patent No. 12,467,091). The patent covers the use of Polygenic Risk Scores for predicting disease complications and response to therapy. This milestone strengthens OPTITHERA’s intellectual property portfolio, developed with CHUM and Les Laboratoires Servier. Patent applications are also […]
GENOCORDIA test receives Health Canada medical device licence
OPTITHERA is proud to announce that its GENOCORDIA test has received a medical device licence from Health Canada. GENOCORDIA is a polygenic risk score test that predicts the risk of cardiovascular and renal complications in people living with type 2 diabetes, from a simple saliva sample. This licence follows the investigational testing authorization obtained in […]
CELEBRATING CANADIAN EXCELLENCE AND ACHIEVEMENT IN HEALTH: THE CANADIAN MEDICAL HALL OF FAME ANNOUNCES THE 2026 INDUCTEES
EMBARGOED UNTIL 12:00 PM (EDT) Thursday, October 2, 2025 London, ON – Lehana Thabane, PhD, Chair of the Canadian Medical Hall of Fame (CMHF), announced today that after a thorough nomination and selection process, the remarkable contributions and achievements of six Canadians will be honoured with induction into the CMHF: Pavel Hamet, CM OQ […]
Authorization from Health Canada for Medical Device Investigational Testing
August 12, 2024, OPTITHERA obtained and Investigational testing authorization for medical devices from Health Canada, to sell its test for investigational testing to the investigators of the clinical study entitled: New Genomic predictor for complication risk in type 2 diabetes (GENOCORDIA). The objective of the study is to provide Real World Evidence (RWE) on the […]
A World-First in Genomics, a Saliva Test to Predict Complications Associated with Type 2 Diabetes, Powered by an Important Public-Private Partnership
A new agreement has been signed between OPTITHERA, ELNA Medical Group, and Génome Québec as part of Genome Canada’s Genomic Applications Partnership Program (GAPP). This partnership will ensure the final steps required to bring to market the first-ever genomic test predicting the risk of diabetic complications.
Genome Canada funding supports impact-focused genomics research and development projects.
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced more than $41 million in government and private funding in support to eight new genomics research projects funded through Genome Canada’s Genomic Applications Partnership Program (GAPP).
Génome Québec allocates $ 1,9 M to the OPTITHERA project.
Génome Québec is particularly proud of the performance of Québec teams in a pan-Canadian competition. Over $23 million will be invested in genomics in Québec, including $5.4 million through Génome Québec. In fact, 49% of the available Canadian envelope was allocated to Québec projects. These investments will accelerate the commercialization and increase its real-world applications.
OPTITHERA’s scientists contribute to shared data resources on prioritized genes of kidney function decline to help drug development pipelines.
Need more information about this research?